News from 2012
Dr Roger M. Perlmutter Joins Heptares’ Board of Directors
Welwyn Garden City, UK and Boston, MA, USA, 22 October 2012 – Heptares Therapeutics, the leading GPCR drug discovery company, has elected Dr Roger M. Perlmutter, the former Executive Vice President, Research and Development, at Amgen Inc. to its Board of Directors as a Non-executive Director.
FDA Advisory Committee Recommends Approval of Aegerion’s Drug - Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia
FDA Advisory Committee Recommends Approval of Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Pulmagen Therapeutics signs partnership with Teijin Pharma
Pulmagen signs license for Japanese rights for its lead product ADC 3680. Pulmagen’s drug acts by a novel anti-inflammatory mechanism, binding CRTh2. Pulmagen’s drug is currently in a Phase II asthma study. Teijin will be responsible for clinical development for the Japanese market.
European Commission approves Esmya® for the pre-operative treatment of uterine fibroids
Gedeon Richter Plc. has announced that the European Commission has granted marketing authorisation to Esmya® 5mg tablet as pre- operative treatment of moderate to severe symptoms of uterine fibroids.